What's in SK Chemicals Co., Ltd.'s pipeline?

SK Chemicals Co., Ltd. has 35 drugs in our index: 2 marketed, 0 filed, 18 in Phase 3, 4 in Phase 2, 11 in Phase 1.

Which companies overlap with SK Chemicals Co., Ltd.'s portfolio?

Top competitors by shared drug class: GlaxoSmithKline, Sanofi, AstraZeneca, Novartis, Green Cross Corporation.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/sk-chemicals-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

SK Chemicals Co., Ltd. — Portfolio Competitive Intelligence Brief

SK Chemicals Co., Ltd. pipeline: 2 marketed, 0 filed, 18 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 18 Phase 3 4 Phase 2 11 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
GNX80	GNX80	marketed			Other
Ongentys 50mg	Ongentys 50mg	marketed
NBP607-TIV	NBP607-TIV	phase 3	Therapeutic vaccine		Immunology / Infectious Disease
Prodiax-23	Prodiax-23	phase 3	PI3K inhibitor	PI3K	Oncology
SID530, Taxotere	SID530, Taxotere	phase 3	Taxane	Microtubules	Oncology
SID142	SID142	phase 3	SGLT2 inhibitor	SGLT2	Diabetes
SK-PC-B70M	SK-PC-B70M	phase 3	Cancer vaccine (personalized neoantigen vaccine)		Oncology
Agrippal S1	Agrippal S1	phase 3	Inactivated influenza vaccine		Immunology / Infectious Disease
SKCPT	SKCPT	phase 3	SGLT2 inhibitor	SGLT2	Diabetes
Hepabulin IV	Hepabulin IV	phase 3	Anticoagulant (albumin-heparin conjugate)	Factor IIa (thrombin), Factor Xa	Cardiovascular / Hematology
Rinexin® Tab	Rinexin® Tab	phase 3	Renin-angiotensin system inhibitor	Angiotensin II receptor	Cardiovascular
NBP607-Y	NBP607-Y	phase 3			Regenerative Medicine

Therapeutic area mix

Oncology · 4
Immunology / Infectious Disease · 3
Diabetes · 3
Cardiovascular · 2
Endocrinology / Diabetes · 1
Cardiovascular / Hematology · 1
Other · 1
Regenerative Medicine · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

GlaxoSmithKline · 5 shared drug classes
Sanofi · 4 shared drug classes
AstraZeneca · 3 shared drug classes
Novartis · 3 shared drug classes
Green Cross Corporation · 3 shared drug classes
Bayer · 3 shared drug classes
Beijing Tiantan Hospital · 2 shared drug classes
Applied Biology, Inc. · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for SK Chemicals Co., Ltd.:

Cite this brief

Drug Landscape (2026). SK Chemicals Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sk-chemicals-co-ltd. Accessed 2026-05-16.